新型融合蛋白hIFNα1-CB表达载体的构建  

Construction of the recombinant plasmid expressing a novel fusion protein hIFNα1-CB

作　　者：邱定红[1] 毛晓华[1] 徐蘅[1] 李新荣[1] 缪峰[1] 张林元 

机构地区：[1]东南大学基础医学院生物化学与分子生物学系,江苏南京210009 [2]华东医学生物技术研究所,江苏南京210002

出　　处：《东南大学学报（医学版）》2002年第2期133-136,共4页Journal of Southeast University(Medical Science Edition)

基　　金：铁道部科技基金资助项目(JP72013)

摘　　要：目的 :构建人干扰素α1(hIFNα1)和抗菌肽B(CB)的融合蛋白表达质粒。方法 :将人工改造后的hIFNα1基因与CB基因按正确的阅读框架融合 ,并定向克隆至大肠杆菌表达载体pBV2 2 0。结果 :经PCR检测及质粒的限制性分析 ,所挑选的Amp抗性菌落均含有插入了hIFNα1 CB融合基因的重组质粒pHC。结论 :以pBV2 2 0为载体 ,成功构建了hIFNα1 CB融合蛋白表达质粒pHC。Objective To characterize the biological function of hIFN α 1?CB fusion protein,a plasmid expressing this fusion molecule was constructed.Method Artifically modified hIFN α 1 cDNA was fused precisely to the reading frame of CB and further cloned into the E.coli expression vector pBV220.Result All the Amp resistant clonies tested contained the recombinant plasmid pHC,a derivative of pBV220 with the hIFN α 1?CB cDNA inserted downstream of the promoter P RP L by means of PCR and restricted analysis of the plsmid.Conclusion The recombinant plasmid expressing hIFN α 1?CB fusion proteins was successfully constructed.

关 键 词：大肠杆菌 质粒 干扰素Α 抗菌肽B 重组融合蛋白质类 聚合酶链反应 抗病毒药 抗肿瘤药 

分 类 号：R978.7[医药卫生—药品] R979.1[医药卫生—药学]